APL-1091
APL-1091 (Mal-Exo-EEVC-MMAE) is an ADC payload-linker conjugate (Drug-Linker Conjugates for ADC). APL-1091 is formed by the conjugation of the Mal-Exo-EEVC (HY-169353) linker and MMAE (HY-15162), a microtubule inhibitor. APL-1091 resists aggregation at high drug-to-antibody ratio (DAR), exhibits excellent plasma stability, and reduces premature payload release. When conjugated with Trastuzumab (HY-P9907), APL-1091 displays anti-tumor activity in gastric cancer xenograft models. APL-1091 can be used for ADC synthesis and gastric cancer-related research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2921735-87-5
- 分子式: C80H122N14O22
- 分子量:1631.91
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Drug-Linker Conjugates for ADC アイソフォーム固有の製品をすべて表示
More
生物活性
APL-1091 (2.7-10 equiv; 1 h at 20 °C) forms ADCs with Trastuzumab that have favorable hydrophilic properties and minimal aggregation, including a DAR = 8 construct that avoids MMAE-associated aggregation[1].
An antibody-drug conjugate (ADC) is a targeted delivery system composed of a monoclonal antibody, a chemical linker, and a cytotoxic payload, enabling specific payload delivery to target cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2921735-87-5
-
分子量 1631.91
-
分子式 C80H122N14O22
-
SMILES
O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OC(C3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@H](CCC(O)=O)NC([C@@H](NC(C)=O)CCC(O)=O)=O)=O)=O)=O)C(NCCCCCN4C(C=CC4=O)=O)=O)=O)=O)=O)=O)OC)=O
-
別名
Mal-Exo-EEVC-MMAE
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)